Gracy Crane is a cancer biologist by training with a Master in Biomedical Research and a Ph.D. in Cancer Biology. She has also completed post-doctoral training fellowships at Oxford University (UK) and Massachusetts Institute of Technology (USA).
She has over 12 years of years of experience in the pharmaceutical industry, in varying roles including medical and scientific affairs, clinical development, health outcomes research and real world data. For the past 5 years, she has worked on leading the real world evidence strategy for molecules within the rare cancer space within the global Data Science team of the personalized health care department at Roche. Currently, she is the RWD policy lead within the Regulatory Policy team at Roche, and also works on RWD strategies across the product portfolio.
Gracy is part of a number of external steering/working groups including the ISPOR RWD transparency Initiative (https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative); ISPOR-ISPE Special Joint Taskforce on harmonization of RWD protocols, and CIOMs working group on RWD/E guidelines.